Baillie Gifford & Co. Has $22.43 Million Holdings in Exscientia plc (NASDAQ:EXAI)

Baillie Gifford & Co. reduced its position in shares of Exscientia plc (NASDAQ:EXAI - Free Report) by 3.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,397,618 shares of the company's stock after selling 176,787 shares during the quarter. Baillie Gifford & Co. owned about 3.64% of Exscientia worth $22,428,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Exscientia in the 4th quarter worth approximately $207,000. New Republic Capital LLC purchased a new position in Exscientia during the 4th quarter worth $128,000. Jump Financial LLC boosted its holdings in Exscientia by 47.7% in the fourth quarter. Jump Financial LLC now owns 53,755 shares of the company's stock worth $345,000 after acquiring an additional 17,355 shares in the last quarter. Private Advisor Group LLC lifted its stake in shares of Exscientia by 114.3% during the fourth quarter. Private Advisor Group LLC now owns 22,500 shares of the company's stock worth $144,000 after buying an additional 12,000 shares during the period. Finally, Walled Lake Planning & Wealth Management LLC purchased a new stake in shares of Exscientia during the fourth quarter valued at $64,000. 41.58% of the stock is owned by institutional investors.

Exscientia Trading Up 5.6 %

Shares of EXAI stock traded up $0.32 on Friday, hitting $6.00. 704,659 shares of the stock traded hands, compared to its average volume of 636,010. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.30 and a current ratio of 6.30. Exscientia plc has a twelve month low of $3.80 and a twelve month high of $7.91. The firm's 50-day moving average price is $5.27 and its two-hundred day moving average price is $5.39. The stock has a market capitalization of $725.32 million, a PE ratio of -4.58 and a beta of 0.85.

Exscientia (NASDAQ:EXAI - Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The business had revenue of $5.60 million during the quarter. Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. As a group, analysts anticipate that Exscientia plc will post -1.12 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on EXAI shares. Barclays restated an "equal weight" rating and set a $5.00 price objective on shares of Exscientia in a research note on Tuesday, August 13th. TD Cowen reaffirmed a "hold" rating on shares of Exscientia in a report on Friday, August 9th.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.